Engineering PD-L1 Cellular Nanovesicles Encapsulating Epidermal Growth Factor for Deep Second-Degree Scald Treatment

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Immunology

Background:

• Scars are persistent issues after scald wound healing, often inadequately treated by single therapies like epidermal growth factors (EGF).
• Maintaining EGF stability and achieving scarless wound healing are critical clinical challenges.

Purpose of the Study:

• To develop and evaluate engineered nanovesicles co-delivering EGF and PD-L1 for enhanced scald wound healing and scar prevention.
• To investigate the therapeutic mechanisms of EGF@PDL1 NVs in modulating immune responses and promoting skin regeneration.

Main Methods:

• Engineering cellular nanovesicles overexpressing PD-L1 proteins to encapsulate EGF, creating EGF@PDL1 NVs.
• Evaluating the efficacy of EGF@PDL1 NVs in a deep second-degree scald model, assessing immune response and skin cell proliferation.
• Comparing the therapeutic effects of EGF@PDL1 NVs against individual EGF or PD-L1 nanovesicles.

Main Results:

• EGF@PDL1 NVs successfully encapsulated EGF, maintaining its bioactivity.
• The engineered nanovesicles demonstrated significant therapeutic effects by attenuating T cell overactivation and promoting skin cell migration and proliferation.
• EGF@PDL1 NVs significantly improved wound healing and prevented scarring in deep second-degree scalds, outperforming monotherapies.

Conclusions:

• Engineered EGF@PDL1 NVs represent an innovative and effective therapy for deep second-degree scalds.
• This dual-delivery system offers a promising strategy for scarless wound healing by combining immunomodulation and growth factor delivery.
• The study highlights the potential of biomimetic nanocarriers for advanced wound care applications.